Since lymphomas, liver cirrhosis, and interstitial lung disease are critical to differentiate from sarcoidosis, we believe that patients with these conditions should be included in the control group when calculating the specificity of ACE levels for diagnosing sarcoidosis. This evidence concerns the gene ACE and cirrhosis of liver.